In a significant show of confidence, Kelly, the COO of Relmada Therapeutics, has purchased $198,000 worth of stock in the company. This move is noteworthy as it reflects the leadership's belief in the company's future potential and could encourage other investors to consider Relmada as a promising opportunity. Such insider buying often signals positive expectations about the company's performance, making this development important for stakeholders and market watchers.